CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab Plus Irinotecan–Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens

By Yildiz Ramazan   Buyukberber Suleyman   Uner Aytug   Yamac Deniz   Coskun Ugur   Kaya Ali Osman   Ozturk Banu   Yaman Emel   Benekli Mustafa  

Cancer Investigation, Vol. 28, Iss. 1, 2010-01 ,pp. : 33-37

Informa Healthcare

Access to resources Recommend Favorite